Pulike Biological Engineering Inc operates in the Biological products exc. diagnostic sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Pulike Biological Engineering Inc with three other
companies in this sector in CHINA :
Zhejiang Wolwo Bio Pharmaceutical Co Ltd
sales of 639.35 million Chinese Renmimbi [US$94.41 million]
of which 99%
was Pharmaceutical Manufacturing),
Shenzhen Weiguang Biological Products Co Ltd
(821.47 million Chinese Renmimbi [US$121.31 million]
of which 99%
was Blood Products), and
Staidson (Beijing) Biopharmaceuticals Co Ltd
(661.49 million Chinese Renmimbi [US$97.68 million]
of which 100%
was Pharmaceutical manufacturing).
Pulike Biological Engineering Inc reported sales of 663.15 million Chinese Renmimbi (US$97.93 million)
December of 2019.
increase of 9.1%
versus 2018, when the company's sales were 608.06 million Chinese Renmimbi.
Sales of Other Operation saw an increase
that was more than double the company's growth rate: sales were up
31.4% in 2019, from
8.12 million Chinese Renmimbi to 10.66 million Chinese Renmimbi.
Not all segments of Pulike Biological Engineering Inc experienced an increase in sales in 2019:
sales of Technology License and Transfer Income fell 21.8% to 23.54 million Chinese Renmimbi.
(However, this segment's sales were only a very small portion of the company's overall sales).